<?xml version="1.0" encoding="UTF-8"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:content="http://purl.org/rss/1.0/modules/content/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://www.gourt.com/Health/Medicine/Medical-Specialties/Dermatology.html">
<title>Dermatology RSS : Gourt</title>
<link>http://www.gourt.com/Health/Medicine/Medical-Specialties/Dermatology.html</link>
<description></description>
<dc:language>en-us</dc:language>
<dc:rights>Copyright 2007, Gourt.com</dc:rights>
<dc:date>2009-07-02T16:59+41:00
</dc:date>
<dc:publisher>rtruog@gourt.com</dc:publisher>
<dc:creator>rtruog@gourt.com</dc:creator>
<dc:subject>Dermatology RSS : Gourt</dc:subject>
<syn:updatePeriod>hourly</syn:updatePeriod>
<syn:updateFrequency>1</syn:updateFrequency>
<syn:updateBase>1901-01-01T00:00+00:00</syn:updateBase>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_indiana/page_4.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_texas/page_14.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_illinois/page_9.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_pennsylvania/page_4.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_iowa/page_2.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_oregon/page_10.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_new_york/page_11.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_utah/page_2.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_south_carolina/page_1.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_georgia/page_2.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_north_carolina/page_9.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_wisconsin/page_11.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_california/page_14.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_florida/page_14.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_alabama/page_2.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_florida/page_13.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_oregon/page_9.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_louisiana/page_1.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_indiana/page_3.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_ohio/page_5.html" />
  <rdf:li rdf:resource="http://archderm.ama-assn.org/cgi/content/short/145/6/626?rss=1" />
  <rdf:li rdf:resource="http://archderm.ama-assn.org/cgi/content/short/145/6/631?rss=1" />
  <rdf:li rdf:resource="http://archderm.ama-assn.org/cgi/content/short/145/6/634?rss=1" />
  <rdf:li rdf:resource="http://archderm.ama-assn.org/cgi/content/short/145/6/637?rss=1" />
  <rdf:li rdf:resource="http://archderm.ama-assn.org/cgi/content/short/145/6/644?rss=1" />
  <rdf:li rdf:resource="http://archderm.ama-assn.org/cgi/content/short/145/6/652?rss=1" />
  <rdf:li rdf:resource="http://archderm.ama-assn.org/cgi/content/short/145/6/654?rss=1" />
  <rdf:li rdf:resource="http://archderm.ama-assn.org/cgi/content/short/145/6/656?rss=1" />
  <rdf:li rdf:resource="http://archderm.ama-assn.org/cgi/content/short/145/6/659?rss=1" />
  <rdf:li rdf:resource="http://archderm.ama-assn.org/cgi/content/short/145/6/666?rss=1" />
  <rdf:li rdf:resource="http://archderm.ama-assn.org/cgi/content/short/145/6/667?rss=1" />
  <rdf:li rdf:resource="http://archderm.ama-assn.org/cgi/content/short/145/6/677?rss=1" />
  <rdf:li rdf:resource="http://archderm.ama-assn.org/cgi/content/short/145/6/683?rss=1" />
  <rdf:li rdf:resource="http://archderm.ama-assn.org/cgi/content/short/145/6/691?rss=1" />
  <rdf:li rdf:resource="http://archderm.ama-assn.org/cgi/content/short/145/6/695?rss=1" />
  <rdf:li rdf:resource="http://archderm.ama-assn.org/cgi/content/short/145/6/699?rss=1" />
  <rdf:li rdf:resource="http://archderm.ama-assn.org/cgi/content/short/145/6/700?rss=1" />
  <rdf:li rdf:resource="http://archderm.ama-assn.org/cgi/content/short/145/6/704?rss=1" />
  <rdf:li rdf:resource="http://archderm.ama-assn.org/cgi/content/short/145/6/706?rss=1" />
  <rdf:li rdf:resource="http://archderm.ama-assn.org/cgi/content/short/145/6/707?rss=1" />
  <rdf:li rdf:resource="http://archderm.ama-assn.org/cgi/content/short/145/6/710?rss=1" />
  <rdf:li rdf:resource="http://archderm.ama-assn.org/cgi/content/short/145/6/713?rss=1" />
  <rdf:li rdf:resource="http://archderm.ama-assn.org/cgi/content/short/145/6/715?rss=1" />
  <rdf:li rdf:resource="http://archderm.ama-assn.org/cgi/content/short/145/6/715-a?rss=1" />
  <rdf:li rdf:resource="http://archderm.ama-assn.org/cgi/content/short/145/6/715-b?rss=1" />
  <rdf:li rdf:resource="http://archderm.ama-assn.org/cgi/content/short/145/6/715-c?rss=1" />
  <rdf:li rdf:resource="http://archderm.ama-assn.org/cgi/content/short/145/6/715-d?rss=1" />
  <rdf:li rdf:resource="http://archderm.ama-assn.org/cgi/content/short/145/6/715-e?rss=1" />
  <rdf:li rdf:resource="http://archderm.ama-assn.org/cgi/content/short/145/6/715-f?rss=1" />
  <rdf:li rdf:resource="http://archderm.ama-assn.org/cgi/content/short/145/6/715-g?rss=1" />
  <rdf:li rdf:resource="http://archderm.ama-assn.org/cgi/content/short/145/6/722?rss=1" />
  <rdf:li rdf:resource="http://archderm.ama-assn.org/cgi/content/short/145/6/723?rss=1" />
  <rdf:li rdf:resource="http://archderm.ama-assn.org/cgi/content/short/145/6/725?rss=1" />
  <rdf:li rdf:resource="http://archderm.ama-assn.org/cgi/content/short/145/6/732?rss=1" />
 </rdf:Seq>
</items>
</channel>

<item rdf:about="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_indiana/page_4.html">
<title>Permanent Dermatology Job in Not Disclosed Indiana with </title>
<link>http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_indiana/page_4.html</link>
<description><![CDATA[A new practice opportunity northern Indiana is seeking an entrepreneurial Dermatologist for an amazing opportunity to develop a practice with the full support of the physician network, health system and ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_texas/page_14.html">
<title>Locum Tenens Dermatology Job in Not Disclosed Texas with </title>
<link>http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_texas/page_14.html</link>
<description><![CDATA[A dermatology clinic in Tyler, Texas area seeks coverage from August 17 to August 20, 2009. Candidates must be Board Certified, have an active Texas medical license and Texas DPS. Work Monday through ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_illinois/page_9.html">
<title>Permanent DERMATOLOGY Job in Central Illinois Opportunity Illinois with Enterprise Medical Service</title>
<link>http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_illinois/page_9.html</link>
<description><![CDATA[Well respected multi-specialty group in central Illinois in need of additional Dermatologist to join 1 MD and 1 PA due to growth.  New patients have up to 6 months wait for appointment.  No MOHS.  Will ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_pennsylvania/page_4.html">
<title>Permanent DERMATOLOGY Job in Location need Philadelphia Pennsylvania with Enterprise Medical Service</title>
<link>http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_pennsylvania/page_4.html</link>
<description><![CDATA[Two general Dermatologists sought for locations in the Philadelphia area.  Independent contractor positions offering remuneration of $300K and productivity bonuses.  Physicians need to be BE or BC in ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_iowa/page_2.html">
<title>Permanent DERMATOLOGY Job in Ft. Dodge, IA Iowa with Enterprise Medical Service</title>
<link>http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_iowa/page_2.html</link>
<description><![CDATA[Central Iowa healthcare system in need of 3rd general Dermatologist due to patient demand to be employed by multi-specialty group with 2 Derms, 1 NP. No call.  Financial package to include 2 year income ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_oregon/page_10.html">
<title>Permanent DERMATOLOGY Job in Southern Coast of Oregon Oregon with Enterprise Medical Service</title>
<link>http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_oregon/page_10.html</link>
<description><![CDATA[Well established multi-specialty group along beautiful southern coast of Oregon in need of 2 Dermatologist due to upcoming retirement as well as patient demand.  Cosmetic surgery training/experience preferred. ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_new_york/page_11.html">
<title>Permanent DERMATOLOGY Job in One Hour from New York City New York with Enterprise Medical Service</title>
<link>http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_new_york/page_11.html</link>
<description><![CDATA[Wonderful opportunity to join a growing 2 person Dermatology group in MSG within 1 hour of Manhattan in New York.  First year financial package to include attractive base salary, production bonuses, full ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_utah/page_2.html">
<title>Permanent DERMATOLOGY Job in 40 Minutes from Salt. Lake City Utah with Enterprise Medical Service</title>
<link>http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_utah/page_2.html</link>
<description><![CDATA[Well respected physician owned multi-specialty group within 40 minutes of Salt Lake City, UT in need of Dermatologist due to patient demand.  Clinic has EMR system linking all 6 clinical locations.  Financial ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_south_carolina/page_1.html">
<title>Permanent DERMATOLOGY Job in NW South Carolina Area South Carolina with Enterprise Medical Service</title>
<link>http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_south_carolina/page_1.html</link>
<description><![CDATA[Solo Dermatologist needs partner in private practice in NW South Carolina due to growth.  Patients draw area covers 7 counties in a community recognized as one of the top 50 Best Towns in America.  The ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_georgia/page_2.html">
<title>Permanent DERMATOLOGY Job in Southeast Georgia Georgia with Enterprise Medical Service</title>
<link>http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_georgia/page_2.html</link>
<description><![CDATA[Southeast Georgia facility recruiting solo Dermatologist with 100% hospital support to start a new clinic with 160,000 patient draw area.  Option of being employee with $350K base salary, signing bonus, ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_north_carolina/page_9.html">
<title>Permanent DERMATOLOGY Job in Central North Carolina Seek General Derm North Carolina with Enterprise Medical Service</title>
<link>http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_north_carolina/page_9.html</link>
<description><![CDATA[Central North Carolina community hospital within easy drive to Winston-Salem or Charlotte in need of full time Dermatologist due to patient demand.  Walk into busy practice with 100% hospital support ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_wisconsin/page_11.html">
<title>Permanent DERMATOLOGY Job in Southwest Wisconsin Wisconsin with Enterprise Medical Service</title>
<link>http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_wisconsin/page_11.html</link>
<description><![CDATA[Southwest Wisconsin community in need of full time Dermatologist to join1 part time in multi-specialty group due to patient demand.  Financial package to include attractive salary, full benefits, 8 weeks ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_california/page_14.html">
<title>Permanent DERMATOLOGY Job in Great Opportunity located 1 hour from Raleigh California with Enterprise Medical Service</title>
<link>http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_california/page_14.html</link>
<description><![CDATA[A busy, highly respected, solo, single-specialty private practice is seeking an associate.   The current physician is practicing above capacity, and his decision to add an associate is fully supported ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_florida/page_14.html">
<title>Permanent DERMATOLOGY Job in Need for DERM in Central Florida Florida with Enterprise Medical Service</title>
<link>http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_florida/page_14.html</link>
<description><![CDATA[Multi-specialty group in Central Florida is seeking a Dermatologist to join their practice.  The physician will be employed with the option for partnership with NO buy-in.  Partnership track is flexible. ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_alabama/page_2.html">
<title>Permanent DERMATOLOGY Job in North Central Alabama Seeks Dermatologist Alabama with Enterprise Medical Service</title>
<link>http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_alabama/page_2.html</link>
<description><![CDATA[North central Alabama Regional Medical Center in need of full time Dermatologist due to patient demand.  Hospital will assist establishing of solo practice with income guarantee, signing bonus, marketing ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_florida/page_13.html">
<title>Permanent DERMATOLOGY Job in Terrific Opportunity in Naples Florida with Enterprise Medical Service</title>
<link>http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_florida/page_13.html</link>
<description><![CDATA[Well established and respected multi-specialty group in Naples, FL in need of hiring Dermatologist to join 2 due to patient demand and growth.  Call 1:3.  Financial package to include attractive salary, ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_oregon/page_9.html">
<title>Permanent DERMATOLOGY Job in Just Miles from the Pacific Ocean Oregon with Enterprise Medical Service</title>
<link>http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_oregon/page_9.html</link>
<description><![CDATA[New Dermatology opportunity is available in Oregon.  Beautiful location only 1.5 hours to Portland and 3 hours to Seattle.  Hospital based Dermatology position. Excellent benefits and income guarantee. ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_louisiana/page_1.html">
<title>Permanent DERMATOLOGY Job in Southern Louisiana Area Louisiana with Enterprise Medical Service</title>
<link>http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_louisiana/page_1.html</link>
<description><![CDATA[Southern Louisiana community in need of solo Dermatologist due to patient demand.  Hospital will financially sponsor establishing of solo practice with income guarantee, signing bonus, marketing expenses ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_indiana/page_3.html">
<title>Permanent DERMATOLOGY Job in NW Indiana Area Indiana with Enterprise Medical Service</title>
<link>http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_indiana/page_3.html</link>
<description><![CDATA[Well established multi-specialty group in NW Indiana in need of 4th Dermatologist in busy practice. Call 1:4, attractive salary over $250K, signing bonus, production bonus, full benefits including family ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_ohio/page_5.html">
<title>Permanent DERMATOLOGY Job in Southeast Ohio Ohio with Enterprise Medical Service</title>
<link>http://www.physemp.com/physician_jobs/all_dermatology_jobs_in_ohio/page_5.html</link>
<description><![CDATA[Southeast Ohio multi-specialty clinic in need of 2nd full time Dermatologist due to patient demand with over 300k draw area.  No call.  Over 130 physicians for in-house patient referral.  Will be busy/lucrative ]]></description>
</item>

<item rdf:about="http://archderm.ama-assn.org/cgi/content/short/145/6/626?rss=1">
<title>ABOUT THIS JOURNAL: About This Journal</title>
<link>http://archderm.ama-assn.org/cgi/content/short/145/6/626?rss=1</link>
<description><![CDATA[ ]]></description>
</item>

<item rdf:about="http://archderm.ama-assn.org/cgi/content/short/145/6/631?rss=1">
<title>THIS MONTH IN ARCHIVES OF DERMATOLOGY: This Month in Archives of Dermatology</title>
<link>http://archderm.ama-assn.org/cgi/content/short/145/6/631?rss=1</link>
<description><![CDATA[ ]]></description>
</item>

<item rdf:about="http://archderm.ama-assn.org/cgi/content/short/145/6/634?rss=1">
<title>ARCHIVES A CENTURY AGO: Multiple Dactylitis Syphilitica (Phalangitis Heredo-Syphilitica, Hochsinger) in an Infant.</title>
<link>http://archderm.ama-assn.org/cgi/content/short/145/6/634?rss=1</link>
<description><![CDATA[ ]]></description>
</item>

<item rdf:about="http://archderm.ama-assn.org/cgi/content/short/145/6/637?rss=1">
<title>THE CUTTING EDGE: Treatment of Refractory Chronic Urticaria With Sirolimus</title>
<link>http://archderm.ama-assn.org/cgi/content/short/145/6/637?rss=1</link>
<description><![CDATA[ ]]></description>
</item>

<item rdf:about="http://archderm.ama-assn.org/cgi/content/short/145/6/644?rss=1">
<title>STUDY: Thioguanine Nucleotides and Thiopurine Methyltransferase in Immunobullous Diseases: Optimal Levels as Adjunctive Tools for Azathioprine Monitoring</title>
<link>http://archderm.ama-assn.org/cgi/content/short/145/6/644?rss=1</link>
<description><![CDATA[
Objective&nbsp; To prospectively determine optimal levels of 6-thioguanine nucleotide for disease remission in patients with immunobullous disease treated with azathioprine.
Design&nbsp; Prospective, longitudinal study. Laboratory tests and clinical evaluations were performed monthly for 6 months and then every 2 to 3 months (median follow-up, 13.4 months).
Setting&nbsp; Tertiary care medical center.
Patients&nbsp; Twenty-seven patients with immunobullous disease treated with azathioprine were enrolled during a 2-year period. Twelve met the criteria for evaluation of optimal levels of 6-thioguanine nucleotide.
Main Outcome Measures&nbsp; Blood levels of 6-thioguanine nucleotide, 6-methylmercaptopurine, and thiopurine methyltransferase by polymerase chain reaction and enzyme activity were measured longitudinally during treatment.
Results&nbsp; The range of 6-thioguanine nucleotide was 48 to 457 pmol/8&nbsp;x&nbsp;108 red blood cells (RBCs), with an average optimal level of 190.7 pmol/8&nbsp;x&nbsp;108 RBCs for all patients. The mean optimal levels were 179.4 and 205.6 pmol/8&nbsp;x&nbsp;108 RBCs for pemphigus and pemphigoid, respectively. Limited disease required less 6-thioguanine, with a mean of 145.3 pmol/8&nbsp;x&nbsp;108 RBCs. Longitudinal induction of thiopurine methyltransferase activity was observed during treatment. Patients with recalcitrant disease showed higher induction of enzyme activity (with an increase of 9.1 to 23.6 U/mL of RBCs above baseline) than did those with responsive disease.
Conclusions&nbsp; Optimal levels of 6-thioguanine nucleotide metabolites for disease remission in dermatology patients are 150 to 300 pmol/8&nbsp;x&nbsp;108 RBCs. High levels of the inactive metabolite 6-methylmercaptopurine and induction of thiopurine methyltransferase are associated with recalcitrant disease.
]]></description>
</item>

<item rdf:about="http://archderm.ama-assn.org/cgi/content/short/145/6/652?rss=1">
<title>ANNOUCEMENT: Archives Feature</title>
<link>http://archderm.ama-assn.org/cgi/content/short/145/6/652?rss=1</link>
<description><![CDATA[ ]]></description>
</item>

<item rdf:about="http://archderm.ama-assn.org/cgi/content/short/145/6/654?rss=1">
<title>STUDY: Clinical and Mutational Heterogeneity of Darier Disease in Tunisian Families</title>
<link>http://archderm.ama-assn.org/cgi/content/short/145/6/654?rss=1</link>
<description><![CDATA[
Objective&nbsp; To study the mutation spectrum and phenotype-genotype correlation of Darier disease (DD) in Tunisian patients.
Design&nbsp; Case series.
Setting&nbsp; Referral center: Department of Dermatology (La Rabta Hospital), Tunis, Tunisia.
Patients&nbsp; Eight large Tunisian families with DD, with a total of 23 patients and 9 unaffected family members.
Main Outcome Measure&nbsp; Patients were investigated at the clinical, histological, and genetic levels. Families were genotyped with 5 microsatellite markers spanning the ATP2A2 gene. Mutation screening was performed by direct sequencing of the coding region and exon/intron boundaries of the ATP2A2 gene.
Results&nbsp; Typical clinical features of DD were constantly present. Phenotypic variation within and between the studied families was observed. Different neuropsychiatric disorders were seen in 5 families, and various cutaneous and extracutaneous original clinical associations were observed. The haplotype analysis led to the identification of different haplotypes cosegregating with the disease in the studied families. Mutation screening of the ATP2A2 gene revealed 3 recurrent mutations (119-120delAG, R677X, and D702N) and 4 novel variations: 2 missense mutations (G217A and L900R), one microinsertion (2772-2779 ins C), and one microdeletion (1747-1749 del 2T).
Conclusions&nbsp; Our findings provide evidence for clinical and mutational heterogeneity of Tunisian families with DD. No obvious phenotype-genotype correlation was established. To our knowledge, this is the first molecular investigation of DD in the North African population.
]]></description>
</item>

<item rdf:about="http://archderm.ama-assn.org/cgi/content/short/145/6/656?rss=1">
<title>NOTABLE NOTES: Marie Antoinette Syndrome</title>
<link>http://archderm.ama-assn.org/cgi/content/short/145/6/656?rss=1</link>
<description><![CDATA[ ]]></description>
</item>

<item rdf:about="http://archderm.ama-assn.org/cgi/content/short/145/6/659?rss=1">
<title>STUDY: Topical Fluorouracil for Actinic Keratoses and Photoaging: A Clinical and Molecular Analysis</title>
<link>http://archderm.ama-assn.org/cgi/content/short/145/6/659?rss=1</link>
<description><![CDATA[
Objective&nbsp; To examine clinical and molecular changes after topical fluorouracil treatment of photodamaged human facial skin for actinic keratoses.
Design&nbsp; Nonrandomized, open-label 2-week treatment with fluorouracil cream, 5%, followed by clinical and molecular evaluation.
Setting&nbsp; Academic referral center.
Patients&nbsp; Twenty-one healthy volunteers, 56 to 85 years old, with actinic keratoses and photodamage.
Interventions&nbsp; Twice-daily application of fluorouracil cream for 2 weeks and biopsies and clinical evaluation at baseline and periodically after treatment.
Main Outcome Measures&nbsp; Gene and protein expression of molecular effectors of epidermal injury, inflammation, and extracellular matrix remodeling 24 hours after fluorouracil treatment; clinical improvement measured by evaluators, photography, and patient questionnaires.
Results&nbsp; One day after the final fluorouracil treatment, gene expression of the effectors of epidermal injury (keratin 16), inflammation (interleukin 1&beta;), and extracellular matrix degradation (matrix metalloproteinases 1 and 3) was significantly increased. Types I and III procollagen messenger RNA were induced at week 4 (7-fold and 3-fold, respectively). Type I procollagen protein levels were increased 2-fold at week 24. Actinic keratoses and photoaging were statistically significantly improved. Most patients rated photoaging as improved and were willing to undergo the therapy again.
Conclusions&nbsp; Topical fluorouracil causes epidermal injury, which stimulates wound healing and dermal remodeling resulting in improved appearance. The mechanism of topical fluorouracil in photoaged skin follows a predictable wound healing pattern of events reminiscent of that seen with laser treatment of photoaging.
]]></description>
</item>

<item rdf:about="http://archderm.ama-assn.org/cgi/content/short/145/6/666?rss=1">
<title>CALL FOR PAPERS: Notable Notes</title>
<link>http://archderm.ama-assn.org/cgi/content/short/145/6/666?rss=1</link>
<description><![CDATA[ ]]></description>
</item>

<item rdf:about="http://archderm.ama-assn.org/cgi/content/short/145/6/667?rss=1">
<title>STUDY: Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma: Characterization of Clinical Subset With Worse Outcome</title>
<link>http://archderm.ama-assn.org/cgi/content/short/145/6/667?rss=1</link>
<description><![CDATA[
Objectives&nbsp; To identify prognostic factors in primary cutaneous anaplastic large cell lymphoma (pcALCL), focusing on extensive limb disease (ELD), defined as initial presentation or progression to multiple skin tumors in 1 limb or contiguous body regions, and to study gene expression profiles of patients with pcALCL.
Design&nbsp; Retrospective cohort study.
Setting&nbsp; The Stanford Comprehensive Cancer Center and dermatology ambulatory clinics.
Patients&nbsp; A total of 48 patients with pcALCL evaluated from 1990 through 2005.
Main Outcome Measures&nbsp; Hazard ratios (HRs) for prognostic factors for overall survival (OS) and disease-specific survival (DSS) and risk factors for progression to extracutaneous disease were identified using Cox regression. Gene expression profiles of 9 typical pcALCL and 3 ELD samples were investigated using complementary DNA microarrays.
Results&nbsp; Univariate analysis demonstrated age, ELD, and progression to extracutaneous disease as significant prognostic factors for OS, whereas ELD and progression to extracutaneous disease were significant for DSS. In multivariate analysis, age (HR, 1.83; 95% confidence interval [CI], 1.02-3.26) and progression to extracutaneous disease (HR, 6.42; 95% CI, 1.39-29.68) remained significant for OS, whereas ELD (HR, 29.31; 95% CI, 1.72-500.82) and progression to extracutaneous disease (HR, 13.12; 95% CI, 1.03-167.96) remained independent prognostic factors for DSS. Presentation with T3 disease was a risk factor for progression to extracutaneous disease (HR, 10.20; 95% CI, 1.84-56.72). Microarray data revealed that patients with ELD and typical pcALCL formed distinct clusters.
Conclusions&nbsp; Patients with ELD have a more aggressive course associated with a differential gene expression profile. More aggressive treatments may be indicated for patients with ELD and those whose disease progresses to extracutaneous disease because they have poorer outcomes.
]]></description>
</item>

<item rdf:about="http://archderm.ama-assn.org/cgi/content/short/145/6/677?rss=1">
<title>OBSERVATION: Primary Cutaneous T-Cell Lymphoma Localized to the Lower Leg: A Distinct, Locally Aggressive Cutaneous T-Cell Lymphoma</title>
<link>http://archderm.ama-assn.org/cgi/content/short/145/6/677?rss=1</link>
<description><![CDATA[
Background&nbsp; Distinct categories of skin lymphoma with preferential site localization and unique clinical behavior, including leg-type primary cutaneous diffuse large B-cell lymphoma, have recently been described. Although these entities are rare, they exhibit reproducible clinicopathologic features, and their recognition may allow more appropriate treatment protocols.
Observations&nbsp; We describe the distinctive clinicopathologic features that were observed in 3 patients with an unusual variant of primary cutaneous T-cell lymphoma. All cases originated on the legs of elderly patients and exhibited a locally aggressive clinical behavior with relatively rapid relapses after radiotherapy and resistance to other therapies. Histologically, dense dermal-centered infiltrates of atypical, variably sized mature helper T cells were identified. One patient died of progressive disease.
Conclusions&nbsp; Rare cases of primary cutaneous lymphomas do not necessarily fit current criteria for a standard diagnostic category but may represent unique clinicopathologic entities, such as primary cutaneous T-cell lymphoma localized to the lower leg. It is important to be able to identify these unusual lymphoma variants for prognosis and adequate treatment. The aggressive nature of lymphomas preferentially localized on the lower extremities may not be restricted to B-cell or cytotoxic neoplasms.
]]></description>
</item>

<item rdf:about="http://archderm.ama-assn.org/cgi/content/short/145/6/683?rss=1">
<title>OBSERVATION: Ioversol-Induced Acute Generalized Exanthematous Pustulosis: A Case Report</title>
<link>http://archderm.ama-assn.org/cgi/content/short/145/6/683?rss=1</link>
<description><![CDATA[
Background&nbsp; Acute generalized exanthematous pustulosis (AGEP) is a relatively rare exfoliative dermatosis consisting of a generalized eruption of sterile, nonfollicular pustules arising on widespread erythematous and edematous skin that is usually caused by drugs. It has an acute onset, and patients often have systemic manifestations, including leukocytosis, fever, and hemodynamic instability. Rarely has AGEP been associated with radiocontrast dyes.
Observations&nbsp; We describe an 84-year-old man who developed AGEP on 2 separate occasions after receiving an infusion of an ioversol-containing radiocontrast dye.
Conclusion&nbsp; Acute generalized exanthematous pustulosis may occur after the use of intravenous radiocontrast dye.
]]></description>
</item>

<item rdf:about="http://archderm.ama-assn.org/cgi/content/short/145/6/691?rss=1">
<title>OBSERVATION: Pregnancy and Estrogen Receptor {beta} Expression in a Large Congenital Nevus</title>
<link>http://archderm.ama-assn.org/cgi/content/short/145/6/691?rss=1</link>
<description><![CDATA[
Background&nbsp; Large congenital nevi carry a slightly increased risk of melanoma. Pregnancy poses an additional challenge in the monitoring of these patients because little is known regarding the effects of increased estrogen levels on congenital nevi.
Observations&nbsp; A young woman was observed to have clinical lightening of her garment nevus and satellite nevi during 2 sequential pregnancies. Postpartum, the patient experienced darkening and repigmentation in her large garment nevus, with continued lightening of nearby satellite lesions. In addition to photographic documentation of these changes, biopsy samples taken during pregnant and nonpregnant periods underwent immunohistochemical evaluation for estrogen receptor &beta; (ER&beta;), the predominant estrogen receptor in nevi and melanomas. Biopsy samples collected during pregnancy showed a decrease in nuclear staining for ER&beta; compared with samples collected after pregnancy. These changes in ER&beta; expression were not associated with histologic atypia during pregnancy or after delivery.
Conclusions&nbsp; Congenital nevi may be unique in their response to altered estrogen levels. Given the slightly increased risk of melanoma in giant congenital nevi and the dearth of information available regarding the effects of pregnancy on congenital nevi, this case illustrates the need for further study of these pigmented lesions.
]]></description>
</item>

<item rdf:about="http://archderm.ama-assn.org/cgi/content/short/145/6/695?rss=1">
<title>OBSERVATION: Familial Primary Localized Cutaneous Amyloidosis in Brazil</title>
<link>http://archderm.ama-assn.org/cgi/content/short/145/6/695?rss=1</link>
<description><![CDATA[
Background&nbsp; Macular and lichen amyloidosis are clinical variants of primary localized cutaneous amyloidosis (PLCA). Most cases are sporadic, but approximately 10% of cases may be familial. To our knowledge, the clinicopathologic and molecular features of such pedigrees, however, have not been studied in detail.
Observations&nbsp; We assessed 2 Brazilian families with either lichen-type (family 1 had 14 affected subjects) or macular-type (family 2 had 7 affected subjects) PLCA. Typically, in both pedigrees, the onset of symptoms was around puberty, and pruritus usually began on the lower legs. Findings from lesional skin biopsy samples from both families showed thioflavin T&ndash;positive material in the papillary dermis, which was more prominent in the lichen phenotype in family 1. Spontaneous improvement occurred in 3 subjects (from both families) after age 25 years. All affected individuals in family 1 had a heterozygous missense mutation in the OSMR gene (p.I691T), but no pathogenic mutation in OSMR was found in family 2.
Conclusions&nbsp; Familial PLCA shows autosomal dominant inheritance, but there is clinical and genetic heterogeneity and variable clinical penetrance. Demonstration of mutations in the OSMR gene provides new insight into mechanisms of itch and apoptosis in human skin.
]]></description>
</item>

<item rdf:about="http://archderm.ama-assn.org/cgi/content/short/145/6/699?rss=1">
<title>ARCHIVES WEB QUIZ WINNER: March 2009 Archives Web Quiz Winner</title>
<link>http://archderm.ama-assn.org/cgi/content/short/145/6/699?rss=1</link>
<description><![CDATA[ ]]></description>
</item>

<item rdf:about="http://archderm.ama-assn.org/cgi/content/short/145/6/700?rss=1">
<title>EVIDENCE-BASED DERMATOLOGY: STUDY: Association of Psoriasis With Coronary Artery, Cerebrovascular, and Peripheral Vascular Diseases and Mortality</title>
<link>http://archderm.ama-assn.org/cgi/content/short/145/6/700?rss=1</link>
<description><![CDATA[
Objective&nbsp; To examine the cardiovascular risk factors in patients with psoriasis and the association between psoriasis and coronary artery, cerebrovascular, and peripheral vascular diseases.
Design&nbsp; Observational study.
Setting&nbsp; Large Department of Veterans Affairs hospital.
Patients&nbsp; The study included 3236 patients with psoriasis and 2500 patients without psoriasis (controls).
Main Outcome Measures&nbsp; Using International Classification of Diseases, Ninth Revision, Clinical Modification, codes, we compared the prevalence of traditional cardiovascular risk factors and other vascular diseases as well as mortality between patients with psoriasis and controls.
Results&nbsp; Similar to previous studies, we found a higher prevalence of diabetes mellitus, hypertension, dyslipidemia, and smoking in patients with psoriasis. After controlling for these variables, we found a higher prevalence not only of ischemic heart disease (odds ratio [OR], 1.78; 95% confidence interval [CI], 1.51-2.11) but also of cerebrovascular (OR, 1.70; 95% CI, 1.33-2.17) and peripheral vascular (OR, 1.98; 95% CI, 1.32-2.82) diseases in patients with psoriasis compared with controls. Psoriasis was also found to be an independent risk factor for mortality (OR, 1.86; 95% CI, 1.56-2.21).
Conclusions&nbsp; Psoriasis is associated with atherosclerosis. This association applies to coronary artery, cerebrovascular, and peripheral vascular diseases and results in increased mortality.
]]></description>
</item>

<item rdf:about="http://archderm.ama-assn.org/cgi/content/short/145/6/704?rss=1">
<title>EVIDENCE-BASED DERMATOLOGY: RESEARCH COMMENTARY: Adalimumab vs Methotrexate for the Treatment of Chronic Plaque Psoriasis</title>
<link>http://archderm.ama-assn.org/cgi/content/short/145/6/704?rss=1</link>
<description><![CDATA[ ]]></description>
</item>

<item rdf:about="http://archderm.ama-assn.org/cgi/content/short/145/6/706?rss=1">
<title>EVIDENCE-BASED DERMATOLOGY: RESEARCH COMMENTARY: Adalimumab vs Methotrexate for the Treatment of Chronic Plaque Psoriasis--Reply</title>
<link>http://archderm.ama-assn.org/cgi/content/short/145/6/706?rss=1</link>
<description><![CDATA[ ]]></description>
</item>

<item rdf:about="http://archderm.ama-assn.org/cgi/content/short/145/6/707?rss=1">
<title>EDITORIAL: Optimizing Clinical Use of Azathioprine With Newer Pharmacogenetic Data</title>
<link>http://archderm.ama-assn.org/cgi/content/short/145/6/707?rss=1</link>
<description><![CDATA[ ]]></description>
</item>

<item rdf:about="http://archderm.ama-assn.org/cgi/content/short/145/6/710?rss=1">
<title>EDITORIAL: Cutaneous Lymphomas: What Can We Learn From Location?</title>
<link>http://archderm.ama-assn.org/cgi/content/short/145/6/710?rss=1</link>
<description><![CDATA[ ]]></description>
</item>

<item rdf:about="http://archderm.ama-assn.org/cgi/content/short/145/6/713?rss=1">
<title>ON THE HORIZON: Potential New Insight Into the Pathogenesis of Psoriasis</title>
<link>http://archderm.ama-assn.org/cgi/content/short/145/6/713?rss=1</link>
<description><![CDATA[ ]]></description>
</item>

<item rdf:about="http://archderm.ama-assn.org/cgi/content/short/145/6/715?rss=1">
<title>OFF-CENTER FOLD: An Unusual Pruritic Eruption of the Feet--Quiz Case</title>
<link>http://archderm.ama-assn.org/cgi/content/short/145/6/715?rss=1</link>
<description><![CDATA[ ]]></description>
</item>

<item rdf:about="http://archderm.ama-assn.org/cgi/content/short/145/6/715-a?rss=1">
<title>OFF-CENTER FOLD: An Unusual Pruritic Eruption of the Feet--Diagnosis</title>
<link>http://archderm.ama-assn.org/cgi/content/short/145/6/715-a?rss=1</link>
<description><![CDATA[ ]]></description>
</item>

<item rdf:about="http://archderm.ama-assn.org/cgi/content/short/145/6/715-b?rss=1">
<title>OFF-CENTER FOLD: Exophytic Plaques, Blisters, and Mouth Ulcers--Quiz Case</title>
<link>http://archderm.ama-assn.org/cgi/content/short/145/6/715-b?rss=1</link>
<description><![CDATA[ ]]></description>
</item>

<item rdf:about="http://archderm.ama-assn.org/cgi/content/short/145/6/715-c?rss=1">
<title>OFF-CENTER FOLD: Exophytic Plaques, Blisters, and Mouth Ulcers--Diagnosis</title>
<link>http://archderm.ama-assn.org/cgi/content/short/145/6/715-c?rss=1</link>
<description><![CDATA[ ]]></description>
</item>

<item rdf:about="http://archderm.ama-assn.org/cgi/content/short/145/6/715-d?rss=1">
<title>OFF-CENTER FOLD: Annular Patches and Plaques on the Scrotum and Buttocks--Quiz Case</title>
<link>http://archderm.ama-assn.org/cgi/content/short/145/6/715-d?rss=1</link>
<description><![CDATA[ ]]></description>
</item>

<item rdf:about="http://archderm.ama-assn.org/cgi/content/short/145/6/715-e?rss=1">
<title>OFF-CENTER FOLD: Annular Patches and Plaques on the Scrotum and Buttocks--Diagnosis</title>
<link>http://archderm.ama-assn.org/cgi/content/short/145/6/715-e?rss=1</link>
<description><![CDATA[ ]]></description>
</item>

<item rdf:about="http://archderm.ama-assn.org/cgi/content/short/145/6/715-f?rss=1">
<title>OFF-CENTER FOLD: A Violaceous Nodule on the Knee--Quiz Case</title>
<link>http://archderm.ama-assn.org/cgi/content/short/145/6/715-f?rss=1</link>
<description><![CDATA[ ]]></description>
</item>

<item rdf:about="http://archderm.ama-assn.org/cgi/content/short/145/6/715-g?rss=1">
<title>OFF-CENTER FOLD: A Violaceous Nodule on the Knee--Diagnosis</title>
<link>http://archderm.ama-assn.org/cgi/content/short/145/6/715-g?rss=1</link>
<description><![CDATA[ ]]></description>
</item>

<item rdf:about="http://archderm.ama-assn.org/cgi/content/short/145/6/722?rss=1">
<title>RESEARCH LETTERS: Patients&#x27; Fears and Expectations: Exploring the Hidden Agenda in Our Consultation</title>
<link>http://archderm.ama-assn.org/cgi/content/short/145/6/722?rss=1</link>
<description><![CDATA[ ]]></description>
</item>

<item rdf:about="http://archderm.ama-assn.org/cgi/content/short/145/6/723?rss=1">
<title>CORRESPONDENCE: Calciphylaxis Associated With Chronic Inflammatory Conditions, Immunosuppression Therapy, and Normal Renal Function: A Report of 2 Cases</title>
<link>http://archderm.ama-assn.org/cgi/content/short/145/6/723?rss=1</link>
<description><![CDATA[ ]]></description>
</item>

<item rdf:about="http://archderm.ama-assn.org/cgi/content/short/145/6/725?rss=1">
<title>CORRESPONDENCE: Lentigo Maligna Melanoma With Folliculotropism: Dermoscopic Features During Rapid Progression</title>
<link>http://archderm.ama-assn.org/cgi/content/short/145/6/725?rss=1</link>
<description><![CDATA[ ]]></description>
</item>

<item rdf:about="http://archderm.ama-assn.org/cgi/content/short/145/6/732?rss=1">
<title>SKINSIGHT: New Dermoscopic Pattern in Actinic Keratosis and Related Conditions</title>
<link>http://archderm.ama-assn.org/cgi/content/short/145/6/732?rss=1</link>
<description><![CDATA[ ]]></description>
</item>

</rdf:RDF>